Navamepent
 | |
| Clinical data | |
|---|---|
| Other names | RX-10045 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C18H24O4 |
| Molar mass | 304.386 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Navamepent (RX-10045) is a synthetic analogue[1] of the endogenous fatty acid resolvin E1, a member of the specialized pro-resolving mediators. Navamepent is presumed to act as an agonist of the CMKLR1 receptor in a manner similar to resolvin E1.
It was developed as a topical ophthalmic formulation to promote recovery from eye inflammation and advanced to Phase II clinical trials, but was not pursued further.[2][3][4]
References
[edit]- ↑ WO 2010120719, Gjorstrup P, Schwartz CE, "Compositions and methods for the treatment of inflammation", published 21 October 2010, assigned to Resolvyx Pharmaceuticals, Inc.
- ↑ Torricelli AA, Santhanam A, Agrawal V, Wilson SE (2014). "Resolvin E1 analog RX-10045 0.1% reduces corneal stromal haze in rabbits when applied topically after PRK". Molecular Vision. 20: 1710–1716. PMC 4279593. PMID 25558174.
- ↑ Hesselink JM, Chiosi F, Costagliola C (2016). "Resolvins and aliamides: lipid autacoids in ophthalmology - what promise do they hold?". Drug Design, Development and Therapy. 10: 3133–3141. doi:10.2147/DDDT.S112389. PMC 5045908. PMID 27729772.
- ↑ Serhan CN (April 2017). "Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms". FASEB Journal. 31 (4): 1273–1288. doi:10.1096/fj.201601222R. PMC 5349794. PMID 28087575.